- Overview of Thyroid Cancer: Most Common Genetic Drivers
- Biomarker Testing in Thyroid Cancer
- Clinical Data and Current Indications of Therapies Targeting Common Genetic Drivers in Advanced Thyroid Cancer
- Audience Question and Answer Session
Date / Time
Maria E. Cabanillas, MD
Department of Endocrine Neoplasia and Hormonal Disorders
The University of Texas MD Anderson Cancer Center
Lori J. Wirth, MD
Massachusetts General Hospital
Harvard Medical School
Sarimar Agosto Salgado, MD
Assistant Member, Endocrine Oncology
Head and Neck-Endocrine Oncology
Moffitt Cancer Center
Marcia Brose, MD, PhD, FASCO
Department of Medical Oncology
Sidney Kimmel Medical College
Thomas Jefferson University
Director, Sidney Kimmel Cancer Center
Vice Chair, Medical Oncology
Sidney Kimmel Medical College
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patient with thyroid cancers.
This program is intended for endocrinologists and other healthcare professionals who care for patients with thyroid cancer.
Upon completion of this activity, participants should be able to:
- Order appropriate assays or molecular tests to detect oncogenic gene fusions in patients with thyroid cancer
- Appraise emerging clinical data supporting the use of TRK inhibition in NTRK fusion–positive thyroid cancer and RET inhibition in RET-altered thyroid cancer
- Manage treatment-related symptoms associated with the treatment of RET-altered or NTRK fusion–positive cancer
- Refer eligible patients with NTRK fusion–positive and RET-altered thyroid cancer for ongoing clinical trials
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.